PKR negatively regulates leukemia progression in association with PP2A activation, Bcl-2 inhibition and increased apoptosis

Blood Cancer Journal

Volumn 3, Issue 9, 2013, Pages

  Cheng, X ^a   Bennett, R L ^a   Liu, X ^a   Byrne, M ^a   Stratford May, W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Bcl 2; Leukemia; PKR; PP2A

Indexed keywords

DOXORUBICIN; FINGOLIMOD; LUCIFERIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN BCL 2; PROTEIN KINASE R;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DEPHOSPHORYLATION; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; LEUKEMIA CELL; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR VOLUME;

EID: 84885357375     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.42     Document Type: Article

References (40)

1. Ito T, Jagus R, May WS. Interleukin 3 stimulates protein synthesis by regulating double-stranded RNA-dependent protein kinase. Proc Natl Acad Sci USA 1994; 91: 7455-7459. (Pubitemid 24238202)
2. Bennett RL, Blalock WL, Abtahi DM, Pan Y, Moyer SA, WS May. RAX, the PKR activator, sensitizes cells to inflammatory cytokines, serum withdrawal, chemotherapy, and viral infection. Blood 2006; 108: 821-829. (Pubitemid 44154613)
3. Hsu LC, Park JM, Zhang K, Luo JL, Maeda S, Kaufman RJ et al. The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature 2004; 428: 341-345. (Pubitemid 38418807)
4. Li YJ, Zeng JM, Huang SF, Wang XZ, Zhao SQ, Bai WJ et al. Selective leukemia cell death by activation of the double-stranded RNA-dependent protein kinase PKR. Int J Mol Med 28: 215-222.
5. Murad JM, Tone LG, de Souza LR, De Lucca FL. A point mutation in the RNAbinding domain I results in decrease of PKR activation in acute lymphoblastic leukemia. Blood Cells Mol Dis 2005; 34: 1-5. (Pubitemid 40017973)
6. Liu X, Bennett RL, Cheng X, Byrne M, Reinhard MK, May Jr WS. PKR regulates proliferation, differentiation, and survival of murine hematopoietic stem/progenitor cells. Blood 2013; 121: 3364-3374.
7. Bennett RL, Pan Y, Christian J, Hui T, May Jr WS. The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and activation, leading to G(1) arrest. Cell Cycle 2012; 11: 407-417.
8. Ruvolo VR, Kurinna SM, Karanjeet KB, Schuster TF, Martelli AM, McCubrey JA et al. PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells. J Biol Chem 2008; 283: 35474-35485.
9. Deb A, Haque SJ, Mogensen T, Silverman RH, Williams BR. RNA-dependent protein kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT1- independent pathway. J Immunol 2001; 166: 6170-6180. (Pubitemid 32440747)
10. Goh KC, deVeer MJ, Williams BR. The protein kinase PKR is required for p38 MAPK activation and the innate immune response to bacterial endotoxin. EMBO J 2000; 19: 4292-4297. (Pubitemid 30623740)
11. Abraham N, Jaramillo ML, Duncan PI, Methot N, Icely PL, Stojdl DF et al. The murine PKR tumor suppressor gene is rearranged in a lymphocytic leukemia. Exp Cell Res 1998; 244: 394-404. (Pubitemid 28507055)
12. Beretta L, Gabbay M, Berger R, Hanash SM, Sonenberg N. Expression of the protein kinase PKR in modulated by IRF-1 and is reduced in 5q- associated leukemias. Oncogene 1996; 12: 1593-1596. (Pubitemid 26132048)
13. Blalock WL, Bavelloni A, Piazzi M, Faenza I, Cocco L. A role for PKR in hematologic malignancies. J Cell Physiol 223: 572-591.
14. Hii SI, Hardy L, Crough T, Payne EJ, Grimmett K, Gill D et al. Loss of PKR activity in chronic lymphocytic leukemia. Int J Cancer 2004; 109: 329-335. (Pubitemid 38252759)
15. Yeung MC, Liu J, Lau AS. An essential role for the interferon-inducible, doublestranded RNA-activated protein kinase PKR in the tumor necrosis factor-induced apoptosis in U937 cells. Proc Natl Acad Sci USA 1996; 93: 12451-12455.
16. Pataer A, Raso MG, Correa AM, Behrens C, Tsuta K, Solis L et al. Prognostic significance of RNA-dependent protein kinase on non-small cell lung cancer patients. Clin Cancer Res 2010; 16: 5522-5528.
17. Savinova O, Joshi B, Jagus R. Abnormal levels and minimal activity of the dsRNAactivated protein kinase, PKR, in breast carcinoma cells. Int J Biochem Cell Biol 1999; 31: 175-189. (Pubitemid 29094798)
18. Bennett RL, Carruthers AL, Hui T, Kerney KR, Liu X, May Jr WS. Increased expression of the dsRNA-activated protein kinase PKR in breast cancer promotes sensitivity to doxorubicin. PLoS One 2012; 7: e46040.
19. Kim SH, Forman AP, Mathews MB, Gunnery S. Human breast cancer cells contain elevated levels and activity of the protein kinase, PKR. Oncogene 2000; 19: 3086-3094. (Pubitemid 30438465)
20. Barber GN, Wambach M, Thompson S, Jagus R, Katze MG. Mutants of the RNAdependent protein kinase (PKR) lacking double-stranded RNA binding domain I can act as transdominant inhibitors and induce malignant transformation. Mol Cell Biol 1995; 15: 3138-3146.
21. Donze O, Jagus R, Koromilas AE, Hershey JW, Sonenberg N. Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells. EMBO J 1995; 14: 3828-3834.
22. Meurs EF, Galabru J, Barber GN, Katze MG, Hovanessian AG. Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1993; 90: 232-236. (Pubitemid 23010284)
23. Wickremasinghe RG, Hoffbrand AV. Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. Blood 1999; 93: 3587-3600. (Pubitemid 29249803)
24. Xu Z, Williams BR. The B56alpha regulatory subunit of protein phosphatase 2A is a target for regulation by double-stranded RNA-dependent protein kinase PKR. Mol Cell Biol 2000; 20: 5285-5299. (Pubitemid 30431582)
25. Ruvolo PP, Deng X, May WS. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 2001; 15: 515-522. (Pubitemid 32266720)
26. Deng X, Gao F, May WS. Protein phosphatase 2A inactivates Bcl2's antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding. Blood 2009; 113: 422-428.
27. Wang YY, Deng X, Xu L, Gao F, Flagg T, May WS. Bcl2 enhances induced hematopoietic differentiation of murine embryonic stem cells. Exp Hematol 2008; 36: 128-139.
28. Deng X, Gao F, Flagg T, May Jr. WS. Mono- and multisite phosphorylation enhances Bcl2's antiapoptotic function and inhibition of cell cycle entry functions. Proc Natl Acad Sci USA 2004; 101: 153-158. (Pubitemid 38084219)
29. May WS, Tyler PG, Ito T, Armstrong DK, Qatsha KA, Davidson NE. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. J Biol Chem 1994; 269: 26865-26870. (Pubitemid 24332884)
30. Ruvolo PP, Clark W, Mumby M, Gao F, May WS. A functional role for the B56 alphasubunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function. J Biol Chem 2002; 277: 22847-22852. (Pubitemid 34967266)
31. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007; 117: 2408-2421. (Pubitemid 47494343)
32. Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol 2003; 138: 1303-1312. (Pubitemid 36543128)
33. Perrotti D, Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev 2008; 27: 159-168.
34. Wallington-Beddoe CT, Don AS, Hewson J, Qiao Q, Papa RA, Lock RB et al. Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia. PLoS One 2012; 7: e36429.
35. Yang Y, Huang Q, Lu Y, Li X, Huang S. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation. J Cell Biochem 2012; 113: 1314-1322.
36. Bialojan C, Takai A. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem J 1988; 256: 283-290.
37. Mai H, May WS, Gao F, Jin Z, Deng X. A functional role for nicotine in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 2003; 278: 1886-1891. (Pubitemid 36801428)
38. Ettenger R, Schmouder R, Kovarik JM, Bastien MC, PF Hoyer. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants. Pediatr Transplant 2011; 15: 406-413.
39. Fazekas F. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group. Wien Med Wochenschr 2012; 162: 354-366.
40. Seshacharyulu P, Pandey P, Datta K, Batra SK. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett 2013; 335: 9-18.